"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue.BOSTON, May 19, 2026 ...

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...

Mavenclad (cladribine) is a medicine used to treat relapsing forms of multiple sclerosis (MS) including relapsing-remitting MS and active secondary progressive MS. Relapsing forms of MS have temporary ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

Frexalimab (Sanofi), a novel, investigational second-generation inhibitor of the CD40 ligand, significantly reduced disease activity in relapsing multiple sclerosis (MS) and was well tolerated in a ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).

The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Secondary progressive multiple sclerosis (SPMS) can develop after relapsing-remitting multiple sclerosis (RRMS). It causes steady neurological decline, either with or without relapses. Switching from ...

Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.